What is the price target for CTSO stock?
8 analysts have analysed CTSO and the average price target is 5.36 USD. This implies a price increase of 711.36% is expected in the next year compared to the current price of 0.66.
CYTOSORBENTS CORP (CTSO) Forecast, Price Target & Analyst Ratings
NASDAQ:CTSO • US23283X2062
Current stock price
0.66 USD
+0.02 (+3.45%)
At close:
0.66 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYTOSORBENTS CORP (CTSO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.05
- Revenue Estimate
- 9.778M
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.36
Upside
+ 711.36%
From current price of $0.66 to mean target of $5.36, Based on 8 analyst forecasts
Low
$0.76
Median
$5.10
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for CTSO. The average price target is 5.36 USD. This implies a price increase of 711.36% is expected in the next year compared to the current price of 0.66.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
CTSO was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CTSO.
In the previous month the buy percentage consensus was at a similar level.
CTSO was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-14 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-09-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-15 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-15 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-05-02 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-03 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-04-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-08 | EF Hutton | Maintains | Buy -> Buy |
| 2024-11-04 | EF Hutton | Maintains | Buy -> Buy |
| 2024-10-22 | EF Hutton | Maintains | Buy -> Buy |
| 2024-10-01 | EF Hutton | Maintains | Buy -> Buy |
| 2024-08-14 | EF Hutton | Maintains | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.05
- Revenue Estimate
- 9.778M
- Revenue Q2Q
- 6.86%
- EPS Q2Q
- 63.57%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-7.82%
EPS (1 Month)
0.00%
EPS (3 Months)
-25.00%
Next Earnings Summary
CTSO is expected to report earnings on 3/25/2026. The consensus EPS estimate for the next earnings is -0.05 USD and the consensus revenue estimate is 9.78M USD.
The next earnings revenue estimate has been revised downward by 7.82% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 34.69M -19.64% | 31.085M -10.39% | 35.595M 14.51% | 38.188M 7.29% | 41.59M 8.91% | 50.063M 20.37% | 85.982M 71.75% | 130.45M 51.72% | 277.47M 112.70% | 343.33M 23.74% | 452.77M 31.88% | |
| EBITDA YoY % growth | -30.64M -39.21% | -29.831M 2.64% | -14.882M 50.11% | -11.412M 23.32% | -1.255M 89.01% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -31.52M -38.61% | -31.293M 0.72% | -16.452M 47.43% | -2.262M 86.25% | -6.987M -208.84% | -3.98M 43.04% | 25.447M 739.37% | 59.878M 135.30% | 174.91M 192.11% | 224.48M 28.34% | 306.69M 36.62% | |
| Operating Margin | -90.86% | -100.67% | -46.22% | -5.92% | -16.80% | -7.95% | 29.60% | 45.90% | 63.04% | 65.38% | 67.74% | |
| EPS YoY % growth | -0.76 -33.33% | -0.65 14.47% | -0.38 41.54% | -0.17 55.26% | -2.84 -1,567.97% | -0.06 97.84% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.05 63.57% | -0.04 -104.00% | -0.04 -219.00% | -0.03 38.80% | -0.01 80.00% |
| Revenue Q2Q % growth | 9.778M 6.86% | 9.881M 13.22% | 10.81M 12.41% | 10.68M 12.60% | 11.262M 15.18% |
| EBITDA Q2Q % growth | N/A | 918K 126.09% | -308.04K 89.16% | -310.08K 82.02% | 224.4K |
| EBIT Q2Q % growth | -3.924M 2.50% | -1.297M 66.62% | -677.28K 81.26% | -670.14K 76.58% | -126.48K 96.78% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
22.52%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
8.04%
Revenue Next 5 Year
26.87%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CYTOSORBENTS CORP / CTSO Forecast FAQ
When does CYTOSORBENTS CORP (CTSO) report earnings?
CYTOSORBENTS CORP (CTSO) will report earnings on 2026-03-25, before the market open.
What are the consensus estimates for CYTOSORBENTS CORP (CTSO) next earnings?
The consensus EPS estimate for the next earnings of CYTOSORBENTS CORP (CTSO) is -0.05 USD and the consensus revenue estimate is 9.78M USD.
Can you provide the consensus rating for CYTOSORBENTS CORP stock?
The consensus rating for CYTOSORBENTS CORP (CTSO) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.